|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
ZA737247B
(en)
|
1972-09-29 |
1975-04-30 |
Ayerst Mckenna & Harrison |
Rapamycin and process of preparation
|
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
AU643109B2
(en)
|
1990-12-14 |
1993-11-04 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
DE69233204T2
(de)
|
1991-12-13 |
2004-07-15 |
Xoma Corp., Berkeley |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
|
WO1993015210A1
(en)
|
1992-01-23 |
1993-08-05 |
Merck Patent Gmbh |
Monomeric and dimeric antibody-fragment fusion proteins
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
AU675223B2
(en)
|
1992-05-08 |
1997-01-30 |
Creative Biomolecules, Inc. |
Chimeric multivalent protein analogues and methods of use thereof
|
|
EP0656946B2
(en)
|
1992-08-21 |
2010-03-31 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
WO1994007921A1
(en)
|
1992-09-25 |
1994-04-14 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US6972193B1
(en)
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
PL310327A1
(en)
|
1993-02-12 |
1995-12-11 |
Univ Leland Stanford Junior |
Adjustable transcription of target genes and other biological processes
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
JP4105761B2
(ja)
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン（マクロライド）の半合成類似体免疫調節剤
|
|
SG64372A1
(en)
|
1993-12-17 |
1999-04-27 |
Novartis Ag |
Rapamycin derivatives
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
DE69528894T2
(de)
|
1994-05-02 |
2003-03-27 |
Bernd Groner |
Bifunktionelles protein, herstellung und verwendung
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
JP3659261B2
(ja)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
組換体タンパク質の多機能性複合体への標的化ヘテロ結合
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
WO1996025953A1
(en)
|
1995-02-24 |
1996-08-29 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
JPH11508126A
(ja)
|
1995-05-23 |
1999-07-21 |
モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー |
多量体タンパク質
|
|
US5696135A
(en)
|
1995-06-07 |
1997-12-09 |
Gpi Nil Holdings, Inc. |
Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
|
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
|
BR9606706A
(pt)
|
1995-10-16 |
1999-04-06 |
Unilever Nv |
Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
ES2225961T3
(es)
|
1996-04-04 |
2005-03-16 |
Unilever N.V. |
Proteina de union a antigeno multivalente y multiespecifica.
|
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
WO1998006842A1
(en)
|
1996-08-16 |
1998-02-19 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
AU744160B2
(en)
|
1996-10-25 |
2002-02-14 |
Cell Genesys, Inc. |
Targeted cytolysis of cancer cells
|
|
WO1998048837A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
WO1998056906A1
(en)
|
1997-06-11 |
1998-12-17 |
Thoegersen Hans Christian |
Trimerising module
|
|
EP0985039B1
(en)
|
1997-06-12 |
2008-02-20 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
PT1003861E
(pt)
|
1997-08-01 |
2007-01-31 |
Schering Corp |
Proteínas de membrana de células de mamíferos;reagentes relacionados
|
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
|
BR9813276A
(pt)
|
1997-10-27 |
2000-08-22 |
Unilever Nv |
Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
|
|
GB9725764D0
(en)
|
1997-12-04 |
1998-02-04 |
Isis Innovation |
HLA-E binding
|
|
WO1999037791A1
(en)
|
1998-01-23 |
1999-07-29 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Multipurpose antibody derivatives
|
|
CA2319236A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
WO1999052552A1
(en)
|
1998-04-15 |
1999-10-21 |
Brigham & Women's Hospital, Inc. |
T cell inhibitory receptor compositions and uses thereof
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
ATE251181T1
(de)
|
1998-07-28 |
2003-10-15 |
Micromet Ag |
Heterominikörper
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
JP2002541845A
(ja)
|
1999-04-16 |
2002-12-10 |
セルテック セラピューティックス リミテッド |
合成膜貫通成分
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
AU6085700A
(en)
|
1999-07-12 |
2001-01-30 |
Genentech Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
EP1210425B2
(en)
|
1999-08-17 |
2015-06-17 |
Biogen MA Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
DK1257632T3
(da)
|
2000-02-24 |
2008-01-28 |
Xcyte Therapies Inc |
Samtidig stimulering og opkoncentrering af celler
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
DK1272647T3
(en)
|
2000-04-11 |
2014-12-15 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
WO2002008293A2
(en)
|
2000-07-25 |
2002-01-31 |
Immunomedics Inc. |
Multivalent target binding protein
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
KR100870123B1
(ko)
|
2000-10-20 |
2008-11-25 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 아고니스트 항체
|
|
CA2427858A1
(en)
*
|
2000-11-03 |
2002-05-10 |
University Of Vermont And State Agricultural College |
Compositions for inhibiting grb7
|
|
EP1334188B1
(en)
|
2000-11-07 |
2006-08-30 |
City of Hope |
Cd19-specific redirected immune cells
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
CA2445746C
(en)
|
2001-04-30 |
2012-09-18 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
DE60237282D1
(de)
|
2001-06-28 |
2010-09-23 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
CA2457636C
(en)
|
2001-08-10 |
2012-01-03 |
Aberdeen University |
Antigen binding domains
|
|
EP1293514B1
(en)
|
2001-09-14 |
2006-11-29 |
Affimed Therapeutics AG |
Multimeric single chain tandem Fv-antibodies
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
AU2003210787B2
(en)
|
2002-02-01 |
2009-04-23 |
Medinol Ltd. |
Phosphorus-containing compounds & uses thereof
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
GB0208104D0
(en)
|
2002-04-09 |
2002-05-22 |
Univ Dundee |
Method
|
|
AU2003227504A1
(en)
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
|
EP1618181B1
(en)
|
2003-04-22 |
2014-10-15 |
IBC Pharmaceuticals |
Polyvalent protein complex
|
|
NZ543654A
(en)
|
2003-05-23 |
2009-05-31 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
WO2005000898A2
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
KR20060041205A
(ko)
|
2003-07-01 |
2006-05-11 |
이뮤노메딕스, 인코오포레이티드 |
양특이성 항체들의 다가 담체들
|
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
US20050048617A1
(en)
|
2003-08-18 |
2005-03-03 |
Medimmune, Inc. |
Humanization of antibodies
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
AU2004280333A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Llc |
Humanization of antibodies
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
|
EP1697748A4
(en)
|
2003-12-22 |
2007-07-04 |
Centocor Inc |
METHODS FOR GENERATING MULTIMEDIA MOLECULES
|
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
ES2653570T3
(es)
|
2004-05-27 |
2018-02-07 |
The Trustees Of The University Of Pennsylvania |
Células presentadoras de antígeno artificiales novedosas y usos de las mismas
|
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
CA2577082A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US7994298B2
(en)
*
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
PL1836225T3
(pl)
|
2005-01-06 |
2012-05-31 |
Novo Nordisk As |
Czynniki wiążące kir i sposoby ich stosowania
|
|
ES2657443T3
(es)
|
2005-03-25 |
2018-03-05 |
Gitr, Inc. |
Anticuerpos anti-GITR y usos de los mismos
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
CN101484182B
(zh)
|
2005-04-06 |
2014-06-11 |
Ibc药品公司 |
由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
|
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
PL1899364T5
(pl)
|
2005-05-17 |
2024-12-09 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
|
US20070071759A1
(en)
|
2005-06-29 |
2007-03-29 |
University Of Miami |
Antibody-immune cell ligand fusion protein for cancer therapy
|
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
TWI323734B
(en)
|
2005-08-19 |
2010-04-21 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1757622B1
(en)
|
2005-08-26 |
2009-12-23 |
PLS Design GmbH |
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
|
WO2007041067A2
(en)
*
|
2005-09-29 |
2007-04-12 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for kir genotyping
|
|
WO2007044729A2
(en)
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
JP5102772B2
(ja)
|
2005-11-29 |
2012-12-19 |
ザ・ユニバーシティ・オブ・シドニー |
デミボディ：二量体化活性化治療剤
|
|
PT2529747T
(pt)
|
2005-12-02 |
2018-05-09 |
Icahn School Med Mount Sinai |
Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
|
|
JP5709356B2
(ja)
|
2006-01-13 |
2015-04-30 |
アメリカ合衆国 |
哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
JP2009526857A
(ja)
|
2006-02-15 |
2009-07-23 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
機能性抗体
|
|
US7951918B2
(en)
|
2006-03-17 |
2011-05-31 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
ES2399075T3
(es)
|
2006-08-30 |
2013-03-25 |
Genentech, Inc. |
Anticuerpos multiespecíficos
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
CN101965363A
(zh)
|
2006-11-02 |
2011-02-02 |
丹尼尔·J·卡鹏 |
具有活动部分的杂合免疫球蛋白
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
PT2856876T
(pt)
|
2007-03-30 |
2018-03-28 |
Memorial Sloan Kettering Cancer Center |
Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
|
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
AU2008269032B2
(en)
|
2007-06-27 |
2013-12-05 |
Novartis Ag |
Complexes of IL-15 and IL-15Ralpha and uses thereof
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2626371A1
(en)
|
2007-07-31 |
2013-08-14 |
MedImmune, LLC |
Multispecific epitope binding proteins and uses thereof
|
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
|
EP2212350B1
(en)
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
|
CN101970490A
(zh)
|
2007-11-27 |
2011-02-09 |
埃博灵克斯股份有限公司 |
针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
|
|
DE112008003232T5
(de)
|
2007-11-30 |
2011-02-24 |
Glaxo Group Limited, Greenford |
Antigen-Bindungskonstrukte
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
|
US10059923B2
(en)
|
2008-01-30 |
2018-08-28 |
Memorial Sloan Kettering Cancer Center |
Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
|
|
PL2242773T3
(pl)
|
2008-02-11 |
2017-11-30 |
Cure Tech Ltd. |
Przeciwciała monoklonalne do leczenia nowotworu
|
|
CA2715181A1
(en)
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
CA2735006A1
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
EP2927240A1
(en)
|
2008-08-25 |
2015-10-07 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
PL3006459T3
(pl)
|
2008-08-26 |
2022-01-17 |
City Of Hope |
Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
|
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US9206440B2
(en)
|
2009-01-23 |
2015-12-08 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
|
|
EP2987856B1
(en)
|
2009-02-05 |
2018-07-25 |
Icahn School of Medicine at Mount Sinai |
Chimeric newcastle disease viruses and uses thereof
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
MX2011010332A
(es)
|
2009-04-03 |
2011-11-29 |
S Bio Pte Ltd |
Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
LT2990421T
(lt)
|
2009-04-30 |
2018-04-25 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anti-ceacam1 antikūnai ir jų panaudojimo būdai
|
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
|
CA2772613C
(en)
|
2009-09-03 |
2020-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
|
EP2483301A1
(en)
|
2009-10-01 |
2012-08-08 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
ES2911246T3
(es)
|
2009-11-03 |
2022-05-18 |
Hope City |
Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
|
US9133436B2
(en)
|
2010-02-04 |
2015-09-15 |
The Trustees Of The University Of Pennsylvania |
ICOS critically regulates the expansion and function of inflammatory human Th17 cells
|
|
JP2013527753A
(ja)
|
2010-03-23 |
2013-07-04 |
イントレキソン コーポレーション |
治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
|
|
CN110066339A
(zh)
|
2010-04-20 |
2019-07-30 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
AU2011268110B2
(en)
|
2010-06-19 |
2016-05-19 |
Memorial Sloan-Kettering Cancer Center |
Anti-GD2 antibodies
|
|
WO2011163029A2
(en)
|
2010-06-21 |
2011-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Alkenyl substituted cycloaliphatic compounds as chemical inducers of proximity
|
|
UY33498A
(es)
|
2010-07-09 |
2013-01-03 |
Sanofi Aventis |
Combinaciones de inhibidores de quinasas para el tratamiento de cancer
|
|
KR20130043198A
(ko)
|
2010-07-16 |
2013-04-29 |
피라말 엔터프라이지즈 리미티드 |
키나제 억제제로서 치환된 이미다조퀴놀린 유도체
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
US9493740B2
(en)
|
2010-09-08 |
2016-11-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered GD2-specific T cells
|
|
US9212229B2
(en)
|
2010-09-08 |
2015-12-15 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
WO2012058460A2
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2651442B1
(en)
|
2010-12-14 |
2020-04-22 |
University of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
AU2012207356A1
(en)
|
2011-01-18 |
2013-08-01 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
US9500506B2
(en)
|
2011-03-21 |
2016-11-22 |
Watersign Ltd |
Method and system for stamping and marking fluid in a pipe network for smart monitoring systems
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
KR101976882B1
(ko)
|
2011-03-23 |
2019-05-09 |
프레드 헛친슨 켄서 리서치 센터 |
세포 면역요법용 방법 및 조성물
|
|
JP6082997B2
(ja)
|
2011-04-01 |
2017-02-22 |
メモリアル スローン−ケタリング キャンサー センター |
Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
|
|
CN107188969B
(zh)
|
2011-04-08 |
2021-08-27 |
美国卫生和人力服务部 |
抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
|
|
NZ723731A
(en)
|
2011-04-08 |
2020-05-29 |
Baylor College Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
PH12013502421A1
(en)
|
2011-05-27 |
2014-01-06 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
ES2990023T3
(es)
|
2011-07-25 |
2024-11-28 |
Nationwide Childrens Hospital Inc |
Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4
|
|
PE20141520A1
(es)
|
2011-07-29 |
2014-11-17 |
Univ Pennsylvania |
Receptores coestimuladores de cambio
|
|
AU2012294202B2
(en)
|
2011-08-11 |
2017-02-23 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitor polymorphs
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
SG11201400527XA
(en)
|
2011-09-16 |
2014-04-28 |
Univ Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
EP2765193B1
(en)
*
|
2011-10-07 |
2017-08-09 |
Mie University |
Chimeric antigen receptor
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
WO2013059593A1
(en)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
SG11201401422VA
(en)
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
JP5786681B2
(ja)
|
2011-11-28 |
2015-09-30 |
ブラザー工業株式会社 |
インクジェット記録装置
|
|
EP2785743B1
(en)
|
2011-12-01 |
2019-08-14 |
The Brigham and Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
CA2863799C
(en)
|
2012-02-22 |
2020-09-01 |
Matthew J. FRIGAULT |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
US20130271355A1
(en)
|
2012-04-13 |
2013-10-17 |
Nokia Corporation |
Multi-segment wearable accessory
|
|
FI3597749T3
(fi)
|
2012-05-25 |
2023-10-09 |
Univ California |
Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
JP6482461B2
(ja)
|
2012-07-13 |
2019-03-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
投与に関する形質導入ｔ細胞の適合性の評価方法
|
|
ES2778701T3
(es)
|
2012-07-13 |
2020-08-11 |
The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer |
Gestión de toxicidad para la actividad antitumoral de CAR
|
|
BR112015000310A2
(pt)
|
2012-07-13 |
2017-06-27 |
Univ Pennsylvania |
conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car
|
|
CN104583230A
(zh)
|
2012-07-13 |
2015-04-29 |
宾夕法尼亚大学董事会 |
通过共同引入双特异性抗体增强car t细胞的活性
|
|
EP2872617A4
(en)
|
2012-07-13 |
2015-12-09 |
Univ Pennsylvania |
EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
|
|
BR112015000657B1
(pt)
|
2012-07-13 |
2023-12-05 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula geneticamente modificada para expressar um car
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
PL2884999T3
(pl)
|
2012-08-20 |
2021-07-05 |
Fred Hutchinson Cancer Research Center |
Sposób i kompozycje do immunoterapii komórkowej
|
|
US9937205B2
(en)
|
2012-09-04 |
2018-04-10 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
CN104853776B
(zh)
|
2012-10-12 |
2021-04-09 |
布里格姆及妇女医院股份有限公司 |
免疫应答的增强
|
|
ES2576126T3
(es)
|
2012-12-12 |
2016-07-05 |
The Broad Institute, Inc. |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
LT2956175T
(lt)
|
2013-02-15 |
2017-12-11 |
The Regents Of The University Of California |
Chimerinis antigeno receptorius ir jo panaudojimo būdai
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
KR20210108497A
(ko)
*
|
2013-02-26 |
2021-09-02 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
|
MD4655C1
(ro)
|
2013-03-14 |
2020-06-30 |
Icahn School Of Medicine At Mount Sinai |
Virusurile bolii de Newcastle şi utilizarea acestora
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
FI3888674T3
(fi)
|
2014-04-07 |
2024-07-02 |
Novartis Ag |
Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
|
|
EP3137498A1
(en)
*
|
2014-05-02 |
2017-03-08 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US20170226495A1
(en)
|
2014-07-21 |
2017-08-10 |
Novartis Ag |
Sortase molecules and uses thereof
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
IL303247A
(en)
|
2014-12-29 |
2023-07-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
MX2018003353A
(es)
|
2015-09-17 |
2018-09-17 |
Novartis Ag |
Terapias con celulas cart con una eficacia mejorada.
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
CN109153975A
(zh)
|
2015-12-28 |
2019-01-04 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
JP2019500394A
(ja)
|
2015-12-30 |
2019-01-10 |
ノバルティス アーゲー |
有効性が増強された免疫エフェクター細胞治療
|
|
IL264486B2
(en)
|
2016-07-28 |
2025-04-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|